COR Therapeutics CEO Vaughn Kailian talks to The Wall Street Transcript.

NEW YORK--(BUSINESS WIRE)--Dec. 23, 1998--The Wall Street Transcript has published an in-depth interview with Vaughn M. Kailian of COR Therapeutics, Inc. (Nasdaq:CORR), in which he talks at length about his company's future.

He says, "COR Therapeutics is a biotechnology company whose activities are focused on developing drugs and therapeutics for the treatment of severe cardiovascular diseases. The company is about ten years old. We have about 300 hundred employees, including our sales force. And we currently have one product, INTEGRILIN (tm), which is being commercialized by us and our partner, Schering-Plough, in the United States."

He explains, "We have had INTEGRILAN (tm) on the market since July, and our joint sales forces have been promoting it at full strength since September. We are already stocked in over 800 hospitals in the United States, and well over 60 percent of those have the product on their formularies."

Looking forward, he states, "We're working on an oral blocker of the same receptor. INTEGRILAN (tm) is given intravenously, and it's a very potent inhibitor of a receptor which is called GPIIB-IIIA that allows platelets to stick together and form a clot as they clump up. We're also working on an oral product, a tablet that can be taken orally to treat these same patients after they get released from the hospital and are susceptible to recurring chest pain or heart attacks. Also, we hope this product can be taken to prevent an occurrence from happening in the first place. So the markets do not overlap with the INTEGRILAN(tm) market and really serve to expand the number of severe cardiovascular patients that we're aiming to treat."

To read the complete interview, go to http://www.twst.com/pdf/corr.pdf. It requires Adobe Acrobat (tm) reader to view the document. The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 35 years. The Transcript publishes industry roundtables and interviews with Wall Street analysts, money managers, and Company CEOs, and is read by top money managers, brokers, and individual investors. For subscription information call [phone].